1. Advances in Rheumatoid Arthritis Management

3. This program will include a discussion of investigational agents not approved by the FDA for use in the United States.

4. RA Pathobiology

5. Therapeutic Targets in RA

6. JAK/STAT Pathway: Communication From Transmembrane Receptors to the Nucleus

7. Signaling by Different Cytokines Requires Unique JAK Pairings

8. Signaling by Type I/II Cytokine Receptors and JAK Inhibitors

9. Inhibitory Activity of JAK Inhibitors on JAK1, 2, 3, and TYK2 (IC50 nM)

10. JAK Inhibitors In Vitro Cytokine Inhibition, Does Specificity Matter?

11. Tofacitinib Phase 3 Trial Design

12. Tofacitinib Phase 3 Trials Results

13. Baricitinib Phase 3 RA Program

14. Baricitinib Phase 3 Trials Results

15. Upadacitinib Phase 3 Program

16. Upadacitinib Phase 3 Trial Results

17. Filgotinib Phase 3 Program

18. Filgotinib Phase 3 Trials Results

19. Jakinib Safety

20. JAK Inhibitors and Concern About Herpes Zoster

21. Jakinibs Possible Laboratory Changes

22. Baricitinib Total DVT/PE Incidence Rates by Analysis Set

23. VTE Incidence Rates in RA Patients Observational Databases

24. JAK Inhibitors and Concern About VTEs

25. Indications for FDA-Approved JAK Inhibitors

26. 2016 ACR Treatment Algorithm for Established RA

27. Would You Use a JAK Inhibitor Before a Biologic in a csDMARD-IR?

28. Can You Switch From One JAK Inhibitor to Another in Cases of Nonresponders?

29. Abbreviations

30. Abbreviations (cont)

31. Abbreviations (cont)